1 / 54

Polyneuropathies Mononeuropathies Motoneuron diseases

Polyneuropathies Mononeuropathies Motoneuron diseases. Zsuzsanna Arányi. Peripheral nerve. Motor, sensory and autonomic fibers Fiber types according to diameter: A fibers- 1-17 μ m in diameter; myelinated motor and sensory fibers B fibers- 1-3 μ m in diameter; myelinated autonomic fibers

blythe
Download Presentation

Polyneuropathies Mononeuropathies Motoneuron diseases

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. PolyneuropathiesMononeuropathiesMotoneuron diseases Zsuzsanna Arányi

  2. Peripheral nerve • Motor, sensory and autonomic fibers • Fiber types according to diameter: • A fibers- 1-17 μm in diameter; myelinated motor and sensory fibers • B fibers- 1-3 μm in diameter; myelinated autonomic fibers • C fibers- 0.3-1.3 μm in diameter; non-myelinated autonomic and pain fibers

  3. Types of peripheral nerve damage Demyelination • Slowed conduction: no symptoms • Conduction block: weakness and sensory loss, but no atrophy Axonal damage (axonotmesis) • Degeneration of axons distal to the lesion (denervation) • Weakness, sensory loss, atrophy Neurotmesis • Damage to axons and epineurium • Weakness, sensory loss, atrophy • No regeneration without nerve suture

  4. Nerve regeneration – reinnervation Remyelination Proximo-distal axon regeneration Collateral reinnervation (in case of partial nerve damage) 2-12 weeks 1 mm/day Intact basal lamina/endoneuriumis needed Starts within 4-6 weeks

  5. Polyneuropathies • Generalised disease of the peripheral nervous system (nerve roots and peripheral nerves) • Usually the longest nerves are affected first • Symptoms start on the toes, feet • Usually the symptom of an underlying systemic disease • Search for etiology!

  6. Classification of polyneuropathies • Clinical presentation • Symmetric • Asymmetric • Time course • Acute • Chronic • Etiology • Pathology • Axonal • Demyelinative • Small-fiber

  7. Clinical forms of polyneuropathies • Chronic, symmetric, distal and predominantly sensory polyneuropathies • Mononeuropathy multiplex • Purely motor or sensory polyneuropathies • Autonomic polyneuropathies • Acute polyneuropathies

  8. Typical symptoms of polyneuropathies • Chronic course • Symmetric, distal paraesthesia, pain and hypaesthesia in stocking – glove distribution; feet are affected first • Allodynia • Depressed or absent tendon reflexes • Distally pronounced muscle weakness, with wasting, fasciculation • Gait disorder • Sensory ataxia • Weakness • Autonomic dysfunction (reduced sweating, tachycardia, urinary disturbances, gastroparesis etc.)

  9. Typical complaints of patients with polyneuropathies • Tingling, pin-prick, numbness, burning or cold sensation, burning pain (especially during the night) • ‘Ants crawling on my legs’ • ‘As if I had tight boots on’ • ‘As if I were walking on a duvet’ • ‘As if I had stockings on when really not’ • ‘As if my skin were thick on my soles’ • Unstable gait, ‘dizziness’ • Loss of dexterity of the hands: ‘I drop objects’

  10. Causes of polyneuropathy • Metabolic-endocrine disturbances: diabetes mellitus, uremia etc. • Vitamin deficiencies: vitamin B1 -alcoholism, malabsorption, malnutrition, vitamin B12 • Toxic causes: heavy metals, industrial solvents, drugs, alcohol • Dysimmune polyneuropathies • With manifestation only in the peripheral nervous system: acute inflammatory demyelinative polyneuropathy (Guillain-Barré syndrome), chronic inflammatory demyelinative polyneuropathy (CIDP), multifocal motor neuropathy (MMN) • Systemic diseases: vasculitis (polyarteritis nodosa, SLE etc.), paraproteinaemias • Paraneoplasia • Infectious: lepra, Lyme-disease, HIV • Hereditary: Charcot-Marie-Tooth disease etc. • Other: critical illness polyneuropathy, small-fiber neuropathy • Idiopathic

  11. Investigation of polyneuropathies • ENG-EMG • Blood tests: We, blood count, glucose, hepatic and renal function • Vitamin B12 • Thyroid function • Se electrophoresis, autoanti-bodies, cryoglobulin • Serological examinations (HIV, Lyme, HCV) • Search for tumors • CSF • Toxicological investigations • Sural nerve biopsy • Genetic tests

  12. Treatment of polyneuropathies • Treat the cause! • Immune therapy • plasmapheresis: Guillain-Barré syndrome, CIDP • immunoglobulins: MMN, Guillain-Barré syndrome, CIDP • corticosteroids: CIDP, systemic vasculitis • Symptomatic treatment of paraesthesias and neuropathic pain • antiepileptic medications (carbamazepine, gabapentin, pregabalin) • tricyclic antidepressants (amitriptilin, clomipramin) • SNRI antidepressants (duloxetin, venlafaxin) • Vitamin B1: alcoholism, malabsorption, malnutrition

  13. Polyneuropathies associated with diabetes mellitus • Distal symmetric sensory polyneuropathy • Mononeuropathies- carpal tunnel syndrome, ulnar nerve lesion • Cranial nerve lesions- oculomotor nerve palsy • Autonomic neuropathy- sexual and urinary disturbance, gastroparesis and diarrhoea etc. • Diabetic amyotrophy- painful, asymmetric, proximal weakness (plexopathy?) • Radiculopathy- lumbar, thoraco-abdominal

  14. Diabetic chronic distal symmetric sensory polyneuropathy • The most common form of diabetic neuropathy • Prevalence among diabetic patients: 20-60% • Present at the diagnosis of diabetes in 20% of patients • May be the only manifestation of impaired glucose tolerance • Severity is usually proportional to the duration and severity of hyperglycemia • Prevalence increases with age and duration of diabetes • Small fibers (pain, temperature, light touch) are preferentially affected →painful diabetic neuropathy in about 20-35% • Autonomic dysfunction • Trophic alterations →diabetic foot

  15. Small fiber neuropathy- skin biopsy NormalSmall fiber neuropathy Epidermal nerve fibers (arrow): anti PGP 9.5 antibodies Fibrous tissue and basal lamina: anti collagen IV antibodies

  16. Symptoms of sensory diabetic neuropathy I. • Length-dependent: first symptoms on the toes and feet • Later stocking-gloves distribution • Usually doesn’t go above the knees and elbows • If symptoms appear on the hands first → carpal tunnel syndrome • Areflexia • Trophic changes

  17. Symptoms of sensory diabetic neuropathy II. • Positive sensory symptoms: • burning pain (pronounced during the night) • hyperesthesia, allodynia • paresthesia • Negative sensory symptoms: • hypesthesia (loss of sensation)

  18. Diabetic foot • Related to diabetic sensory neuropathy and peripheral artery disease • Diabetic foot ulcers precede 85% of non-traumatic lower limb amputations • Life-time prevalence of foot ulcers is 15% in diabetic patients

  19. Guillain-Barré syndrome • Acute immunmodulated poly-radiculo-neuro-pathy • Pathology: perivascular lymphocyte-macrophage infiltration in the peripheral nervous system leading to macrophage mediated segmental demyelination • Incidence: 1.5-2.0/100 000/year • In most cases preceded by an infection (upper respiratory tract infection, diarrhoea) • Infectious agents associated with Guillain-Barré syndrome: CMV, EBV, HIV, Campylobacter jejuni, Mycoplasma pneumoniae • The infectious agent is usually unidentified

  20. Pathomechanism of GBS

  21. Guillain-Barré syndrome- symptoms • Acute, symmetric ascending flaccid paralysis • Variable severity • Respiratory insufficiency • Bilateral facial palsy • Ascending numbness to a lesser degree • Radicular pain • Areflexia • Autonomic symptoms- tachycardia, cardiovascular instability

  22. Guillain-Barré syndrome- time course • Symptoms evolve over 1-2 weeks • Plateau is reached within 2-3 weeks • Spontaneous recovery within a few months • Good prognosis • Prognosis is determined mainly by complications of being bed-bound (infection, thrombosis etc.)

  23. Guillain-Barré syndrome- diagnosis Normal neurography Segmental demyelination Conduction block Temporal dispersion

  24. Guillain-Barré syndrome- diagnosis and treatment • Diagnosis • Clinical symptoms • Electroneurography- confirms segmental demyelination • Cerebrospinal fluid examination: elevated protein content with normal cell count (starting from the 2nd week) • Treatment • Plasmapheresis, immunoglobulin (IVIG) • Supportive treatment!

  25. Chronic inflammatory demyelinative polyneuropathy (CIDP) • Autoimmune disease • Prevalence: 1-2/100 000 • Course: • chronic monophasic (15%) • chronic relapsing-remitting (34%) • step-wise progressive (34%) • continuously progressive (15%) • Symptoms: proximal and distal motor and sensory symptoms, cranial symptoms (not a length-dependent neuropathy) • Rarely associated with central nervous system demyelination (3%)

  26. Diagnosis of CIDP • ENG/EMG: segmental (non-uniform) demyelination • CSF: protein >45 mg/dl, cell count <10 • Histology (biopsy): not obligatory, may be normal • chronic demyelination-remyelination may lead to Schwann-cell proliferation (‘onion bulb’ formation) • infiltration of inflammatory cells • MRI: hypertrophy of peripheral nerves and nerve roots, contrast enhancement

  27. CIDP- nerve biopsy ‘onion bulbs’

  28. CIDP- MRI Hypertrophied trigeminal nerves

  29. CIDP treatment • IVIG • 2 g/kg bw in 2-5 days, monthly for 3 months • maintanance treatment • Corticosteroids • methylprednisolon 1 mg/kg bw, later gradual reduction • Plasmapheresis

  30. Mononeuropathies- causes • Trauma • cutting, laceration and stretching of the nerve • Compression • often iatrogenic • Tunnel syndromes • Ischemia

  31. Localisation of focal nerve lesions • A partial proximal nerve lesion may selectively affect only one nerve fascicle → clinically the lesion appears more distal • The longer axons are more sensitive to compression → distal symptoms are more pronounced

  32. Median nerve

  33. Distal median nerve damage: carpal tunnel syndrome • Incidence: 200-500/100 000/year, 3 times more common in women • Symptoms: • Painful paraesthesia of the hand during the night, pain in the whole arm • First the dominant hand is affected, but bilateral involvement in most cases • Advanced symptoms: sensory loss on digits 1-3, thenar atrophy and weakness • Causes: idiopathic, overuse, change of tunnel anatomy (fracture, arthrosis, oedema etc.), diabetes • Treatment: • Splinting of the hand during the night • Surgery

  34. Proximal median nerve damage 1. 1. Weakness of all median nerve muscles ‘oath hand’ 2. 2. Weakness of flexion of the distal phalanx of digit 1-2 no sensory loss

  35. Ulnar nerve

  36. Ulnar nerve lesion at the elbow- two types Extension Flexion • Retroepicondylar lesion (more common) • Compression, elbow fracture, arthrosis, diabetes • Real cubital tunnel syndrome

  37. Ulnar nerve lesion • Numbness of digit 4-5 and ulnar edge of the hand • Atrophy and weakness of hypothenar, interosseus muscles and adductor pollicis muscle • Tinel-sign at the elbow • Claw hand

  38. Radial nerve

  39. Radial nerve lesion on the upper arm • ‘Saturday night palsy’: nerve compression during sleep • common in alcoholics • Symptoms: weakness of wrist and finger extension (wrist drop); triceps is normal;loss of sensation on the dorsal-radial aspect of the hand

  40. Radial nerve lesion on the forearm • Weakness of finger extension (‘finger drop’), extension of the wrist is only sightly weak, oftens starts on digit 4-5 → may be confused with ulnar nerve lesion • No sensory loss • Causes: supinator tunnel syndrome due to overuse

  41. Common peroneal nerve

  42. Peroneal nerve damage at the fibular head • Foot drop, steppage gate • Supination (inversion) and plantarflexion is normal • Sensory loss on the lateral aspect of the leg and dorsal aspect of the foot • Causes: compression • During sleep, in coma • During surgery • Cast • Crossed legs • Squatting (strawberry pickers) • Peroneal tunnel syndrome?

  43. Motoneuron diseases • Progressive loss/degeneration of motoneurons • Weakness • Atrophy • No sensory or autonomic symptoms • Two major types: • Amyotrophic lateralsclerosis (ALS): both upper and lower motoneurons are affected • Spinal muscular atrophies / lower motoneuron syndromes

  44. ALS First described by Jean Martin Charcot in 1874 • Incidence: 2 / 100 000 / year • Prevalence: 6 / 100 000 ‘Lou Gehrig’s disease’

  45. ALS- Clinical forms • Sporadic ALS • Classic ALS • Progressive muscular atrophy (PMA) • Primary lateralsclerosis • Progressive bulbar paralysis • Progressive pseudobulbar palsy • Familial ALS (5-10%) • Autosome dominant • SOD1 mutations • No SOD1 mutations • Autosome recessive • SOD1 mutation • Chronic juvenile ALS • X-linked • Frontotemporal dementia+ ALS (ubiquitin positive) Progressive muscular atrophy (PMA) Lower motoneuron onset Classic ALS Upper motoneuron onset Bulbar onset Progressive bulbar paralysis Primary lateralsclerosis

  46. ALS- symptoms and course • Mixed signs of upper and lower motor neuron lesion • Atrophy, fasciculation, cramps • Spasticity, increased reflexes, Babinski • Relentlessly and quickly progressive • Average survival: 2-5 years • Cause of death: respiratory insufficiency

  47. ALS- Clinical syndromes at onset • Asymmetric small hand muscle atrophy and weakness (segmental distribution)- 60-85% • Diff. dg.: radiculopathy, ulnar nerve lesion • Proximal arm muscle atrophy and weakness (‘flail’ arm) • Diff. dg.: radiculopathy • Bulbar onset- 15-40% • Dysarthria and dysphagia • Diff. dg.: myasthenia gravis, pseudobulbar paresis • Spastic paraparesis • Diff. dg: spinal disease

  48. ALS symptoms

  49. ALS- treatment • No cure • Only drug approved for ALS: riluzol (inhibits the presynaptic release of glutamate), survival on riluzol increases by 3-6 months • Supportive treatment: • Muscle relaxants • Antidepressants, anxiolytic drugs • PEG in case of severe dysphagia • Assistive devices • Ventilation??? (moral issue) Riluzol trials

  50. Infantile and juvenile spinal muscular atrophies (SMA I-III) • 1 / 6-20 000 live births • Autosome recessive • In 95% of patients the mutation is found in the SMN (survival motoneuron) gene (chr. 5)

More Related